Health Condition 1: M1A- Chronic gout
Conditions
Interventions
Intervention1: Habb-e-Leemun
: One tablet Taken orally twice a day after meals with water for 6 weeks.
Control Intervention1: NIL: NIL
Sponsors
Central Council for Research in Unani Medicine CCRUM New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Conformed diagnosis of gout meeting ACR criteria (American College of Rheumatology Criteria) for gout. 2. History of recurrent gout flares (more than 2 per year). 3. Persistent symptoms such as joint pain, swelling, or tophi (visible urate deposits) present for at least six months. 4. Chronic hyperuricemia (serum uric acid equal or more than 6.8).
Exclusion criteria
Exclusion criteria: 1. Known cases of joints diseases (Osteoarthritis, Osteomyelitis, Rheumatoid Arthritis) except Gout. 2. Patients with systemic diseases like Diabetes Mellitus, Hypertension, and Cardiovascular diseases. 3. Grade-2 obesity (BMI more than 35). 4. Hepatic and renal insufficiency and any malignancy. 5. Patient on long term medication. 6. Patients on drugs that increase uric acid levels. (Thiazide diuretics) or decrease calcium levels (furosemide). 7. Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of the Habb -e- Leemun in the treatment of Niqris (Chronic Gout) will be carried out on the basis of Pain (VAS-Visual Analogue Scale) and Gout Assessment Questionnaire.Timepoint: At baseline, at first follow up and at the end of treatment. i.e., 0, 2nd, 6th weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological and biochemical investigations for safety assessment i.e., Hemogram, LFT, KFT,Serum Uric acid, HbA1c, CRP and Urine Examination: Routine & Microscopic. Timepoint: At baseline, at first follow up and at the end of treatment. i.e., 0, 2nd, 6th weeks | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine (CCRUM)
Outcome results
None listed